Asset Details
Do you wish to reserve the book?
AB0405 IMPACT OF THE HLA-Cw60602 ALLELE AND IFIH1/MDA5 GENE VARIANTS ON CARDIOMETABOLIC RISK FACTORS IN PATIENTS WITH PSORIATIC DISEASE
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
AB0405 IMPACT OF THE HLA-Cw60602 ALLELE AND IFIH1/MDA5 GENE VARIANTS ON CARDIOMETABOLIC RISK FACTORS IN PATIENTS WITH PSORIATIC DISEASE
Do you wish to request the book?
AB0405 IMPACT OF THE HLA-Cw60602 ALLELE AND IFIH1/MDA5 GENE VARIANTS ON CARDIOMETABOLIC RISK FACTORS IN PATIENTS WITH PSORIATIC DISEASE
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
AB0405 IMPACT OF THE HLA-Cw60602 ALLELE AND IFIH1/MDA5 GENE VARIANTS ON CARDIOMETABOLIC RISK FACTORS IN PATIENTS WITH PSORIATIC DISEASE
2024
Overview
Background:The HLA-Cw6 allele has been shown to be the main driver of the genetic burden of psoriatic disease and has also been associated with marked phenotypic traits. Recently, associations have been found between this biomarker and some cardiometabolic factors such as hypertension and visceral adiposity1-3.Objectives:We aimed to analyze the associations between some psoriasis-related genetic biomarkers and the presence of cardiometabolic risk factors.Methods:Cross-sectional observational study of 572 patients with psoriatic disease (30% PsA). The following genetic biomarkers were determined: HLA-Cw6*0602 allele (SNP rs1050414 C/G) and the IFIH1/MDA5 gene variants: rs35337543, intron8 + 1G>C; rs35744605, Glu627Stop; and rs1990760, Ala946Thr. The potential associations between these markers and cardiometabolic risk factors were investigated both by crude and adjusted regression models (software R 4.3.1 “Beagle Scouts”).Results:We included 309 (54%) men and 263 women (46%). Table 1 summarizes the main characteristics of the study population. Regarding PsA, associations with psoriasis severity (OR: 2.14), female sex (OR: 1.63), and the rs1990760 TT genotype (OR: 1.62) were found, while HLA-Cw6 positivity resulted protective (OR: 0.65). Cw6+ patients had a lower waist perimeter with an average of 2.37 cm less, however this difference was explained by age, female sex and arthritis. These subjects had on average 0.81 units less in BMI, but again this difference was explained by age, female sex, and arthritis. The Cw6+ patients weighed on average 2.3 kg less than the Cw6 negative patients, but this difference was explained by female sex and arthritis. The presence of this marker was associated with a reduction in the risk of hypertension (OR: 0.52, 95% CI: 20-66), however this difference lost significance after adjustment for age and arthritis. Cw6 positive subjects had a lower risk of diabetes (OR: 0.36, 95%CI: 0.19-0.63), however this association was lost after adjusting for age. We found no association between cardiometabolic comorbidity and IFIH1/MDA5 gene variants.Conclusion:The apparent protection conferred by HLA-Cw6 against the development of hypertension, diabetes or a greater visceral adiposity was explained by other variables such as age, sex or arthritis. Since the worldwide distribution of HLA-Cw6 is not uniform, these findings need further confirmation.REFERENCES:[1] Biomed Res Int 2022; 2022: 1451193.[2] J Invest Dermatol 2022; 142(6): 1617-1628.[3] Acta Derm Venereol 2023; 103: adv5209.Table 1.Distribution of study variables stratified by sexVariablesMen, n: 309Women, n: 263Total, n: 572Age (yrs), mean (SD)47.5 (14.6)45.7 (14.3)46.7 (14.5)Age at disease onset (yrs), median (min, max)24.5 [1.00, 74.0]20.0 [1.00, 78.0]23.0 [1.00, 78.0]Disease duration (yrs), mean (SD)18.7 (14.3)20.3 (15.4)19.4 (14.8)PsA, n (%)81 (26.2)90 (34.2)171 (30)Weight, mean (SD)85.4 (14.6)69.3 (13.9)77.9 (16.4)BMI, mean (SD)28.5 (4.43)26.7 (5.48)27.6 (5.02)Waist perimeter (cm), mean (SD)101 (11.6)91.4 (14.7)96.7 (14.1)PASI, mean (SD)16.0 (11.9)14.0 (12.0)15.1 (12.0)PASI ≥ 10, n (%)174 (56.3)120 (45.6%)294 (51.4%)Nail disease, n (%)192 (62.1)136 (51.7%)328 (57.3%)Plaque psoriasis, n (%)281 (90.9)216 (82.1)497 (86.9)Smoking, n (%)99 (32.0)97 (36.9)196 (34.3)alcohol consumption (SDU), median (min, max)0 [0, 2.00]0 [0, 30.0]0 [0, 30.0]T1D, n (%)11 (3.6)11 (4.2)22 (3.8)T2D, n (%)29 (9.4)16 (6.1)45 (7.9)Hypertension, n (%)68 (22.0)46 (17.5)114 (20.0)Dyslipidemia, n (%)68 (22.0)45 (17.1)113 (19.8)NAFLD, n (%)99 (32.0)30 (11.4)129 (22.6)Patients with adverse coronary events, n (%)20 (6.5)13 (4.9)33 (5.8)Patients on systemic therapy, n (%)203 (65.7)167 (63.5)370 (64.7)yrs: years; PsA: psoriatic arthritis; BMI: body mass index; PASI: psoriasis area and severity index; SDU: standard drink unit; T1D: type 1 diabetes; T2D: type 2 diabetes; NAFLD: non-alcoholic fatty liver disease.Acknowledgements:NIL.Disclosure of Interests:None declared.
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism,Elsevier B.V,Elsevier Limited
